Financhill
Sell
30

ZYME Quote, Financials, Valuation and Earnings

Last price:
$12.56
Seasonality move :
14.48%
Day range:
$12.23 - $13.17
52-week range:
$7.97 - $17.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.18x
P/B ratio:
2.52x
Volume:
577.8K
Avg. volume:
568.9K
1-year change:
13.74%
Market cap:
$852.3M
Revenue:
$76.3M
EPS (TTM):
-$1.61

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ZYME
Zymeworks
$45.2M -$0.09 107.34% -75.24% $21.35
ALNY
Alnylam Pharmaceuticals
$580.6M -$0.14 20.07% -15.81% $304.87
ARVN
Arvinas
$62.8M -$0.96 71.95% -5.19% $45.26
CATX
Perspective Therapeutics
$267.3K -$0.25 -- -41.72% $15.58
STOK
Stoke Therapeutics
$4.3M -$0.53 72.2% -8.77% $23.88
VREX
Varex Imaging
$202.2M $0.04 0.27% 358.33% $21.20
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ZYME
Zymeworks
$12.25 $21.35 $852.3M -- $0.00 0% 12.18x
ALNY
Alnylam Pharmaceuticals
$241.76 $304.87 $31.3B -- $0.00 0% 13.73x
ARVN
Arvinas
$8.43 $45.26 $579.7M -- $0.00 0% 2.30x
CATX
Perspective Therapeutics
$2.59 $15.58 $175.1M -- $0.00 0% 13.99x
STOK
Stoke Therapeutics
$8.60 $23.88 $455.5M -- $0.00 0% 26.11x
VREX
Varex Imaging
$12.50 $21.20 $515.4M 17.58x $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ZYME
Zymeworks
-- 0.851 -- 3.19x
ALNY
Alnylam Pharmaceuticals
93.86% 2.332 3.37% 2.61x
ARVN
Arvinas
0.11% 1.554 0.05% 4.58x
CATX
Perspective Therapeutics
-- -3.661 -- --
STOK
Stoke Therapeutics
-- 4.255 -- 4.81x
VREX
Varex Imaging
51.21% 1.717 92.11% 2.33x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ZYME
Zymeworks
-- -$22.2M -30.45% -30.45% -71.65% -$41.8M
ALNY
Alnylam Pharmaceuticals
$490.3M -$105.2M -29.16% -- -26.13% -$103.8M
ARVN
Arvinas
-- -$58.2M -32.92% -32.96% -98.31% -$84.4M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
STOK
Stoke Therapeutics
-- -$30M -55.64% -55.64% -613.06% -$21.7M
VREX
Varex Imaging
$68.5M $11.2M -4.56% -8.27% 4.81% $5.3M

Zymeworks vs. Competitors

  • Which has Higher Returns ZYME or ALNY?

    Alnylam Pharmaceuticals has a net margin of -75.75% compared to Zymeworks's net margin of -14.12%. Zymeworks's return on equity of -30.45% beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ZYME
    Zymeworks
    -- -$0.31 $338.8M
    ALNY
    Alnylam Pharmaceuticals
    82.67% -$0.65 $1.1B
  • What do Analysts Say About ZYME or ALNY?

    Zymeworks has a consensus price target of $21.35, signalling upside risk potential of 74.29%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $304.87 which suggests that it could grow by 26.11%. Given that Zymeworks has higher upside potential than Alnylam Pharmaceuticals, analysts believe Zymeworks is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZYME
    Zymeworks
    7 2 0
    ALNY
    Alnylam Pharmaceuticals
    11 9 1
  • Is ZYME or ALNY More Risky?

    Zymeworks has a beta of 1.134, which suggesting that the stock is 13.422% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.76%.

  • Which is a Better Dividend Stock ZYME or ALNY?

    Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZYME or ALNY?

    Zymeworks quarterly revenues are $31M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Zymeworks's net income of -$23.5M is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Zymeworks's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 12.18x versus 13.73x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZYME
    Zymeworks
    12.18x -- $31M -$23.5M
    ALNY
    Alnylam Pharmaceuticals
    13.73x -- $593.2M -$83.8M
  • Which has Higher Returns ZYME or ARVN?

    Arvinas has a net margin of -75.75% compared to Zymeworks's net margin of -76.18%. Zymeworks's return on equity of -30.45% beat Arvinas's return on equity of -32.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZYME
    Zymeworks
    -- -$0.31 $338.8M
    ARVN
    Arvinas
    -- -$0.63 $562.3M
  • What do Analysts Say About ZYME or ARVN?

    Zymeworks has a consensus price target of $21.35, signalling upside risk potential of 74.29%. On the other hand Arvinas has an analysts' consensus of $45.26 which suggests that it could grow by 436.93%. Given that Arvinas has higher upside potential than Zymeworks, analysts believe Arvinas is more attractive than Zymeworks.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZYME
    Zymeworks
    7 2 0
    ARVN
    Arvinas
    13 5 0
  • Is ZYME or ARVN More Risky?

    Zymeworks has a beta of 1.134, which suggesting that the stock is 13.422% more volatile than S&P 500. In comparison Arvinas has a beta of 1.954, suggesting its more volatile than the S&P 500 by 95.435%.

  • Which is a Better Dividend Stock ZYME or ARVN?

    Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZYME or ARVN?

    Zymeworks quarterly revenues are $31M, which are smaller than Arvinas quarterly revenues of $59.2M. Zymeworks's net income of -$23.5M is higher than Arvinas's net income of -$45.1M. Notably, Zymeworks's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 12.18x versus 2.30x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZYME
    Zymeworks
    12.18x -- $31M -$23.5M
    ARVN
    Arvinas
    2.30x -- $59.2M -$45.1M
  • Which has Higher Returns ZYME or CATX?

    Perspective Therapeutics has a net margin of -75.75% compared to Zymeworks's net margin of --. Zymeworks's return on equity of -30.45% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ZYME
    Zymeworks
    -- -$0.31 $338.8M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About ZYME or CATX?

    Zymeworks has a consensus price target of $21.35, signalling upside risk potential of 74.29%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 501.43%. Given that Perspective Therapeutics has higher upside potential than Zymeworks, analysts believe Perspective Therapeutics is more attractive than Zymeworks.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZYME
    Zymeworks
    7 2 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is ZYME or CATX More Risky?

    Zymeworks has a beta of 1.134, which suggesting that the stock is 13.422% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

  • Which is a Better Dividend Stock ZYME or CATX?

    Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZYME or CATX?

    Zymeworks quarterly revenues are $31M, which are larger than Perspective Therapeutics quarterly revenues of --. Zymeworks's net income of -$23.5M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Zymeworks's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 12.18x versus 13.99x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZYME
    Zymeworks
    12.18x -- $31M -$23.5M
    CATX
    Perspective Therapeutics
    13.99x -- -- -$15.1M
  • Which has Higher Returns ZYME or STOK?

    Stoke Therapeutics has a net margin of -75.75% compared to Zymeworks's net margin of -540.05%. Zymeworks's return on equity of -30.45% beat Stoke Therapeutics's return on equity of -55.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZYME
    Zymeworks
    -- -$0.31 $338.8M
    STOK
    Stoke Therapeutics
    -- -$0.47 $232.1M
  • What do Analysts Say About ZYME or STOK?

    Zymeworks has a consensus price target of $21.35, signalling upside risk potential of 74.29%. On the other hand Stoke Therapeutics has an analysts' consensus of $23.88 which suggests that it could grow by 177.62%. Given that Stoke Therapeutics has higher upside potential than Zymeworks, analysts believe Stoke Therapeutics is more attractive than Zymeworks.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZYME
    Zymeworks
    7 2 0
    STOK
    Stoke Therapeutics
    7 1 0
  • Is ZYME or STOK More Risky?

    Zymeworks has a beta of 1.134, which suggesting that the stock is 13.422% more volatile than S&P 500. In comparison Stoke Therapeutics has a beta of 0.988, suggesting its less volatile than the S&P 500 by 1.215%.

  • Which is a Better Dividend Stock ZYME or STOK?

    Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Stoke Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZYME or STOK?

    Zymeworks quarterly revenues are $31M, which are larger than Stoke Therapeutics quarterly revenues of $4.9M. Zymeworks's net income of -$23.5M is higher than Stoke Therapeutics's net income of -$26.4M. Notably, Zymeworks's price-to-earnings ratio is -- while Stoke Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 12.18x versus 26.11x for Stoke Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZYME
    Zymeworks
    12.18x -- $31M -$23.5M
    STOK
    Stoke Therapeutics
    26.11x -- $4.9M -$26.4M
  • Which has Higher Returns ZYME or VREX?

    Varex Imaging has a net margin of -75.75% compared to Zymeworks's net margin of -0.15%. Zymeworks's return on equity of -30.45% beat Varex Imaging's return on equity of -8.27%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZYME
    Zymeworks
    -- -$0.31 $338.8M
    VREX
    Varex Imaging
    34.28% -$0.01 $1.1B
  • What do Analysts Say About ZYME or VREX?

    Zymeworks has a consensus price target of $21.35, signalling upside risk potential of 74.29%. On the other hand Varex Imaging has an analysts' consensus of $21.20 which suggests that it could grow by 69.6%. Given that Zymeworks has higher upside potential than Varex Imaging, analysts believe Zymeworks is more attractive than Varex Imaging.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZYME
    Zymeworks
    7 2 0
    VREX
    Varex Imaging
    3 1 0
  • Is ZYME or VREX More Risky?

    Zymeworks has a beta of 1.134, which suggesting that the stock is 13.422% more volatile than S&P 500. In comparison Varex Imaging has a beta of 0.563, suggesting its less volatile than the S&P 500 by 43.729%.

  • Which is a Better Dividend Stock ZYME or VREX?

    Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ZYME or VREX?

    Zymeworks quarterly revenues are $31M, which are smaller than Varex Imaging quarterly revenues of $199.8M. Zymeworks's net income of -$23.5M is lower than Varex Imaging's net income of -$300K. Notably, Zymeworks's price-to-earnings ratio is -- while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 12.18x versus 0.63x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZYME
    Zymeworks
    12.18x -- $31M -$23.5M
    VREX
    Varex Imaging
    0.63x 17.58x $199.8M -$300K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
49
SMTC alert for Mar 17

Semtech [SMTC] is down 0.49% over the past day.

Buy
62
PLPC alert for Mar 17

Preformed Line Products [PLPC] is up 3.8% over the past day.

Sell
50
NUTX alert for Mar 17

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock